AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
TG Therapeutics to Present at Jefferies Global Healthcare Conference
ByAinvest
Monday, Jun 2, 2025 8:05 am ET1min read
TG Therapeutics announced that CEO Michael S. Weiss will participate in the Jefferies Global Healthcare Conference. Weiss will deliver a fireside chat on June 4, 2025, at 12:50 PM ET. A live webcast of the event will be available on the company's website. TG Therapeutics is a biopharmaceutical company focused on developing treatments for B-cell diseases.
TG Therapeutics Inc. (TGTX) has announced that CEO Michael S. Weiss will participate in the Jefferies Global Healthcare Conference on June 4, 2025, at 12:50 PM ET. The event will feature a fireside chat with Weiss, who will discuss the company's latest advancements and the potential of BRIUMVI® (ublituximab-xiiy), a novel treatment for relapsing forms of multiple sclerosis (RMS).The presentation comes on the heels of positive data from the ULTIMATE I & II Phase 3 trials and the ENHANCE study, which were presented at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting. These trials highlighted BRIUMVI®'s safety and efficacy in treating RMS, with no association between decreased serum immunoglobulin levels and serious infections observed in long-term treatment [1]. Additionally, real-world data from the ENAMOR survey indicated favorable infusion tolerability for BRIUMVI®, and updates from the ENHANCE study confirmed the safety and tolerability of 30-minute infusions [2].
However, the data also raised concerns about infusion reactions and infections. Infusion reactions were reported in 48% of BRIUMVI-treated patients, with serious reactions in 0.6% of cases. Serious infections were slightly higher in BRIUMVI-treated patients compared to those treated with teriflunomide [1]. The drug is contraindicated in patients with active Hepatitis B Virus infection and those with a history of life-threatening infusion reactions [2].
The upcoming conference provides an opportunity for investors to gain insights into TG Therapeutics' strategic direction and the potential market impact of BRIUMVI®. Weiss's participation underscores the company's commitment to addressing unmet needs in RMS treatment and its ability to differentiate BRIUMVI® through unique glycoengineering technology [1].
References:
[1] https://www.gurufocus.com/news/2898276/tg-therapeutics-inc-tgtx-showcases-promising-briumvi-data-at-cmsc-2025-tgtx-stock-news
[2] https://www.globenewswire.com/news-release/2025/05/30/3090994/8790/en/TG-Therapeutics-Announces-Data-Presentations-for-BRIUMVI-in-Multiple-Sclerosis-at-the-2025-Consortium-of-Multiple-Sclerosis-Centers-Annual-Meeting.html
Aime Insights
How might the recent executive share sales at Rimini Street impact investor sentiment towards the company?
What is the current sentiment towards safe-haven assets like gold and silver?
How should investors position themselves in the face of a potential market correction?
How could Nvidia's planned shipment of H200 chips to China in early 2026 affect the global semiconductor market?
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet